Testing effectiveness (Phase 2)Study completedNCT04996797
What this trial is testing
Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
Who this might be right for
Ulcerative Colitis
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 178